The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of the first dose.
Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed
Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
Participants with known mutations in EGFR will be excluded (Group A,B and E).
Participants must not have a history of serious recurrent infections.
Participants must not have a history of severe heart disease.
Single group
BMS-986507
DrugSpecified dose on specified days
Osimertinib
DrugSpecified dose on specified days
Pembrolizumab
DrugSpecified dose on specified days
Nivolumab
DrugSpecified dose on specified days
Pumitamig
DrugSpecified dose on specified days
Number of participants with adverse events (AEs)
Number of participants with serious adverse events (SAEs)
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
Number of participants with AEs leading to discontinuation
Maximum observed serum concentration (Cmax)
Time of maximum observed concentration (Tmax)
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Area under the serum concentration-time curve within a dosing interval (AUC(TAU))
Click on the lead sponsor to view all of their trials.
